SCL Science

SCL Science Interest Expense

The Interest Expense of SCL Science (246960.KQ) as of Nov 4, 2026 is -76.65 M KRW. In the previous year, Interest Expense was 2.22 B KRW — a change of -103.45% (lower).

Interest Expense

-76.65 MKRW

YoY

-103.45%

Last updated:

Interest Expense of SCL Science is 2024 -76.65 M KRW. Interest Expense of SCL Science was 2023 2.22 B KRW. It decreases by -103.45% lower compared to the previous year.

The SCL Science Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-5.40 M KRW
Jan 1, 2018
19.00 M KRW
Jan 1, 2019
-87.20 M KRW
Jan 1, 2020
-368.10 M KRW
Jan 1, 2021
1.34 B KRW
Jan 1, 2022
-1.29 B KRW
Jan 1, 2023
2.22 B KRW
Jan 1, 2024
-76.65 M KRW
The SCL Science Interest Expense history
YEARInterest ExpenseYoY
-76.65 MKRW-103.45%
2.22 BKRW-271.88%
-1.29 BKRW-196.66%
1.34 BKRW-463.71%
-368.10 MKRW+322.13%
-87.20 MKRW-558.95%
19.00 MKRW-451.85%
-5.40 MKRW-100.53%
1.01 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Interest Expense of SCL Science is -76.65 M KRW in 2024.

Interest Expense of SCL Science changed from 2.22 B KRW to -76.65 M KRW, representing a -103.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense SCL Science since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — SCL Science

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — SCL Science